Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSThis webinar is the final part of our three-part series focusing on the third aspect of startups: growth. The launch environment is more pressurized than ever before. The window for success is expanding due to the convergence of legislative requirements, payer expectations for pricing and evidence, and the need to meet patients’ needs.
Now that brand leaders have identified how to best acquire patients and optimize resources, they need to adopt a growth mindset and focus on:
Elyse Muñoz, Ph.D.
Director, U.S. Research & Insights, IQVIA
Brian Lasky
Practice Lead, U.S. Launch Center of Excellence, IQVIA
Nadine Vangelov
Senior Principal, U.S. Launch Center of Excellence, IQVIA
Navigate the challenge of compliance, and its vital association with quality
Grow your brand, now and through patent expiry
